The FDA has issued a complete response letter rejecting Replimune Group’s oncolytic virus therapy RP1 for advanced melanoma, citing inadequate and poorly controlled clinical studies that failed to provide substantial evidence of effectiveness. The rejection was unexpected by the company and led to a significant decline in Replimune’s stock price. Analysts view the decision as indicative of the FDA's increasingly stringent regulatory standards for cell and gene therapies.